Syndax Pharmaceuticals intends to price initial public sale of stock

Deutsche Bank and Jefferies to be joint bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., March 27 - Syndax Pharmaceuticals, Inc. will conduct an initial public offering of its common stock with a 30-day greenshoe, according to a Form S-1 filed Thursday with the Securities and Exchange Commission.

Deutsche Bank Securities Inc. and Jefferies LLC are the joint bookrunning managers. JMP Securities LLC and Wedbush PacGrow Life Sciences are the co-managers.

Proceeds will be used for clinical trials, working capital and general corporate purposes.

The biopharmaceutical company is based in Waltham, Mass. The company intends to list its common stock on the Nasdaq under the symbol "SNDX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.